EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

Merge Healthcare Stock Gaps Down On Today's Open (MRGE)

By TheStreet Wire 05/08/12 - 09:55 AM EDT

Find out if (MRGE) is in Cramer's Portfolio.

NEW YORK (TheStreet) -- Shares of Merge Healthcare (Nasdaq:MRGE) were gapping down Tuesday morning with an open price 17.7% lower than Monday's closing price. The stock closed at $3.95 Monday and opened today's trading at $3.25.

The average volume for Merge Healthcare has been 827,200 shares per day over the past 30 days. Merge Healthcare has a market cap of $356 million and is part of the technology sector and computer software & services industry. Shares are down 20.4% year to date as of the close of trading on Monday.

Merge Healthcare Incorporated provides healthcare information technology solutions in the United States and internationally. Its software solutions automate healthcare data and diagnostic workflow to create an electronic record of the patient experience. The company has a P/E ratio of 5.8, below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Merge Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full Merge Healthcare Ratings Report.

Get more investment ideas from our investment research center.

For more information on Merge Healthcare Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.